事件:根据公司公告,近期公司两款核心自研产品获国家药品监督管理局(NMPA)批准上市:1、公司自主研发首款靶向TROP2 ADC,芦康沙妥珠单抗(sac-TMT,商品名佳泰莱),获批用于治疗既往至少接受过2 种系统治疗不可切除局部晚期或转移性三阴性乳腺癌(TNBC)成人患者。2、公司肿瘤管线核心产品靶向PDL1单抗,塔戈利单抗(KL-A167,商品名科泰莱 ),获批用于治疗后线复发或转移性鼻咽癌...
Source Link事件:根据公司公告,近期公司两款核心自研产品获国家药品监督管理局(NMPA)批准上市:1、公司自主研发首款靶向TROP2 ADC,芦康沙妥珠单抗(sac-TMT,商品名佳泰莱),获批用于治疗既往至少接受过2 种系统治疗不可切除局部晚期或转移性三阴性乳腺癌(TNBC)成人患者。2、公司肿瘤管线核心产品靶向PDL1单抗,塔戈利单抗(KL-A167,商品名科泰莱 ),获批用于治疗后线复发或转移性鼻咽癌...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.